Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tcr2 Therapeutics Inc (NQ: TCRR )

1.460 -0.020 (-1.36%)
Streaming Delayed Price Updated: 12:02 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tcr2 Therapeutics Inc

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Announces Pipeline Priorities for 2023
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
From TCR2 Therapeutics
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.